News | May 23, 2021
Orchid Pharma Q4FY21 consolidated loss at Rs. 24.72 Cr
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
This kit was developed in partnership with Gujarat-based LabCare Diagnostics. LabCare is into clinical chemistry reagents, serology tests, immuno-chromatographic tests and urine analysis strips
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Subscribe To Our Newsletter & Stay Updated
